Cytomedix acquires stem cell company Aldagen

02/8/2012 | MedCityNews.com

Cytomedix purchased Aldagen for $16 million in stock, expanding the former's pipeline of regenerative therapies. The acquisition "provides Cytomedix with a novel, patent-protected cell selection technology that fits well with our existing commercial products and strengthens our long-range growth profile," Cytomedix CEO Martin Rosendale said.

View Full Article in:

MedCityNews.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI